Biomarkers in Lupus Nephritis

Anup Manoharan, Michael P. Madaio

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Biomarkers have the potential to be useful tools for noninvasively evaluating and managing patients with lupus nephritis. Many candidate biomarkers have been identified, but they require validation in larger cohorts. It is likely that combinations or biomarker profiles, rather than individual markers, will emerge to help better predict the severity of inflammation, the extent of fibrosis, degree of drug responsiveness, and other variables. This approach has the potential to reduce the use of the renal biopsy, improve therapeutic efficacy, and limit toxicity. We predict algorithms based on genotype and biomarkers combined with clinical presentation will emerge to help guide physicians in management. Assays that show the most potential include serum erythrocyte bound complement C4d, interleukin 17, interleukin 23, interferon score/chemokine score ratio, and anti-C1q antibodies. Such urinary biomarkers as fractional excretion of endothelial-1, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and TWEAK (tumor necrosis factor-like weak inducer of apoptosis) may also be useful but require validations.

Original languageEnglish (US)
Pages (from-to)131-143
Number of pages13
JournalRheumatic Disease Clinics of North America
Issue number1
StatePublished - Feb 1 2010


  • Assessment of renal functional activity
  • Indicators of Renal flare
  • Noninvasive biomarkers
  • Serologic markers
  • Urinary markers

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Biomarkers in Lupus Nephritis'. Together they form a unique fingerprint.

Cite this